Beijing GoBroad Boren Hospital of GoBroad Medical Institute of Hematology(Beijing Center), affiliated with GoBroad Healthcare Group, was established in Beijing in 2017 as the first flagship hospital. It serves as the center for the diagnosis and treatment of difficult hematology &oncology cases within the Group and is a secondary comprehensive hospital designated by the Beijing Municipal Basic Medical Insurance. The hospital is located by the South Third Ring Road, Fengtai District, Beijing, with a building area of 14,100 square meters and 170 authorized beds. It also features a modern Phase I Clinical Trial Center built according to international standards.
- Success rate of transplantation reaches international leading level
- Renowned immunotherapy center in China
- Leading entity of the China-Net Childhood Lymphoma
- The teaching hospital of Beijing University of Chinese Medicine, and the training base for Hematologists and oncologists
- A strategic partner of Peking Union Medical College (PUMC), Capital Medical University, and School of Medicine, Tsinghua University
- Modern Phase I Clinical Trial Center that meets international standards
- Construction of ARO model, with a professional CRO+SMO team, to explore and practice the research hospital model
- Global labs for precision diagnosis, covering an area of nearly 5,000 square meters, establishing a model for the development of precision medicine
- ISO15189 certification issued by China National Accreditation Service for Conformity Assessment (CNAS) and CAP certification of the US
Led by clinical experts recruited from top medical institutions such as PKU Health Science Center, PUMC, and military hospitals, with leading-edge techniques and rich experience in integrated tumor diagnosis, personalized treatment, and hematopoietic stem cell transplantation.
With a focus on hematology & oncology, the hospital continuously develops and practices innovative characteristic technologies in solid tumors and brain science
Construction – Immunotherapy
From June 2017 to December 2022, a total of 3,601 cases of CAR-T clinical study have been completed, with a complete remission rate of over 80%.
The adverse reactions of CRS are controlled at grade 2 or below, and clinical management of neurotoxicity is proficiently handled, professional AE/SAE medical judgments.
